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Abstract 
Dengue infection is a leading cause of illness
and death in tropical and subtropical regions of
the world. Forty percent of the world’s popula-
tion currently lives in these areas. The clinical
picture  resulting  from  dengue  infection  can
range  from  relatively  minor  to  catastrophic
hemorrhagic  fever.  Recently,  reports  have
increased  of  neurological  manifestations.
Neuropathogenesis  seems  to  be  related  to
direct nervous system viral invasion, autoim-
mune reaction, metabolic and hemorrhagic dis-
turbance. Neurological manifestations include
encephalitis,  encephalopathy,  meningitis,
Guillain-Barré  syndrome,  myelitis,  acute  dis-
seminated  encephalomyelitis,  polyneuropathy,
mononeuropathy, and cerebromeningeal hem-
orrhage. The development of neurological symp-
toms in patients with positive Immunoglobulin
M (IgM) dengue serology suggests a means of
diagnosing  the  neurological  complications
associated with dengue. Viral antigens, specific
IgM antibodies, and the intrathecal synthesis of
dengue  antibodies  have  been  successfully
detected  in  cerebrospinal  fluid.  However,
despite diagnostic advancements, the treatment
of  neurological  dengue  is  problematic.  The
launch of a dengue vaccine is expected to be
beneficial. 
Introduction
Dengue is an RNA virus that is grouped into
four  serotypes  (DENV-1  through  DENV-4)
belonging  to  the  genus  Flavivirus (family
Flaviviridae).1 Dengue  infection  represents
the  most  destructive  arboviral  disease  for
humans. The number of countries reporting
outbreaks has increased 10-fold in the last 30
years and includes more than 100 countries in
the  Pacific-Asian  region,  the  Americas,  the
Middle East, and Africa.2 Approximately 50-100
million infections occur each year resulting in
approximately  25,000  deaths.3-6 The  mosqui-
toes Aedes aegypti and Aedes albopictus are the
vectors that deliver the virus to humans.4 The
disease  has  become  more  common  in  high-
income countries as a result of vector dissem-
ination  and  increased  travel.  Dengue  repre-
sents the second leading cause of acute fever
in travellers.5
The  clinical  spectrum  of  the  disease
ranges  from  dengue  hemorrhagic  fever
(DHF) and dengue shock syndrome to mild
dengue  fever  to  even  oligosymptomatic  or
asymptomatic  infection.6 Because  dengue
infection  can  be  asymptomatic,  the  actual
number  of  cases  of  dengue  infection  has
been underestimated. Recently, neurological
manifestations  have  been  increasingly
described in oligosymptomatic dengue, mak-
ing  it  challenging  to  correlate  neurological
symptoms to the infection.6 The incidence of
infection associated to neurological manifes-
tations ranges from 1% to 5%.7,8 Therefore,
new guidelines for the diagnosis of neurolog-
ical dengue are required, especially for clini-
cians who are unfamiliar with its wide array
of clinical presentations. The most common
neurological  presentations  are  encephalitis
and  encephalopathy,  although  every  year
cases of meningitis, Guillain-Barré syndrome
(GBS),  myelitis,  acute  disseminated
encephalomyelitis, myositis, and neuropathy
have been reported.6-8
In  this  review,  we  analyze  neurological
complications  related  to  dengue  infection,
focusing  on  new  concepts  regarding  the
association of central and peripheral nerv-
ous system involvement and dengue infec-
tion that have recently emerged. Mild cases
of  dengue  encephalitis  with  normal  cere-
brospinal  fluid  (CSF),  patients  with  GBS
without any signs or symptoms of the pre-
ceding infection, the intrathecal synthesis of
specific antibodies, and new laboratory tech-
niques are several of the new findings relat-
ed to neurological dengue that are discussed
in this review.9-11
Neuropathogenesis
The mechanisms of neuropathogenesis fol-
lowing dengue infection seem to be related to
the specific type of neurological disease (Table
1). Viral and host factors have an important
role in the disease pathogenesis.
Metabolic disturbance causing
encephalopathy
Several factors secondary to the infection,
such as cerebral anoxia, shock, edema and/or
toxicity,  caused  by  liver  failure,  thrombocy-
topenia  leading  to  hemorrhages,  and  elec-
trolyte dysfunction are determinants of dengue
encephalopathy and not of encephalitis. It is
crucial  to  differentiate  both  conditions  that
usually occur during DHF and dengue shock
syndrome.12 Secondary  to  thrombocytopenia
and dengue-associated coagulopathy and vas-
culopathy,  an  ischemic  stroke  could  be  trig-
gered.13,14 Pathological studies in fatal cases
revealed non-specific lesions, edema, vascular
congestion, and focal hemorrhages.15
Direct central nervous system
viral invasion
Dengue virus was detected in CSF as early
as 1996, as was the presence of viral antigens
in  the  central  nervous  system  (CNS).16,17
DENV-2 and DENV-3 serotypes are most fre-
quently associated with neurological complica-
tions.16,18 Immunoreactivity  to  DENV-4  has
also been detected in neurons, microglia and
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Non-commercial use onlyendothelial cells.19 However, the mechanisms
underlying neuroinvasion and neurovirulence
are not fully understood. The role of viral fac-
tors in dengue neuropathogenesis was demon-
strated  by  mutating  three  amino  acids  in
DENV-1, mapping to the structural protein E
and  non-structural  protein  NS3  helicase
domains. The E protein seems to be involved in
the pathogenesis of the disease, through the
mediation  of  host-cell  tropism.  These  muta-
tions produced a neurovirulent virus, and the
result was an extensive encephalitis and lep-
tomeningitis in mice.20
Encephalitis is the most common manifesta-
tion secondary to direct viral involvement and
usually develops during the acute phase of infec-
tion. In a study using mice infected by dengue
virus, it was possible to demonstrate that there
was a breakdown of the blood-brain barrier lead-
ing  to  cerebral  vasogenic  edema.  A  dengue-
induced cytokine immune response was respon-
sible for this reaction and it seems to occur in
humans.21 However, it is still not known if the
virus passively crosses the blood-brain barrier
during  the  course  of  systemic  infection  or
whether it actively invades the CNS. 
Other neurological diseases that accompany
the acute febrile period and are related to viral
invasion  are  meningitis,  myositis  and
myelitis.22-24 Specifically,  in  cases  of  myelitis
associated with dengue infection, viral invasion
of  the  spinal  cord  produces  a  specific  local
immune response in the early stage of neuro-
logical disease (intrathecal synthesis of dengue
Immunoglobulin  G  antibodies).9 Detection  of
the local synthesis of monospecific antibodies
may be associated with the pathogenesis of the
disease and indicates viral neurotropism.
Autoimmune reaction
The postinfectious character related to the
immunoallergic  mechanism  can  determine
acute  disseminated  encephalomyelitis,  neu-
romyelitis  optica,  optic  neuritis,  myelitis  or
simply  a  post-infectious  encephalopathy.24,25
The first brain autopsy to confirm this theory
showed a perivenous demyelinating leukoen-
cephalopathy.26 This delayed form of disease is
most frequently observed in adults within 1-3
weeks  of  the  onset  of  infection.  Similarly,
peripheral  involvement,  as  observed  in
Guillain Barré syndrome, might have a similar
postinfectious mechanism.15
Neurological complications
Neurological involvement in dengue infec-
tion was considered to be a rare complication.
However,  recent  reports  of  several  dengue
cases  with  neurological  complications  have
changed this view.7-8,16,27
Encephalitis and meningitis
Encephalitis is the most common neurologi-
cal manifestation of dengue infection.28 Its fre-
quency has been reported to range from 4.2% to
as much as 51%.10,17,28 This difference in fre-
quency depends on the predominant serotype
DENV-2  and  DENV-3  during  epidemics.  The
clinical criteria for dengue encephalitis are:29 i)
fever; ii) acute signs of cerebral involvement,
such  as  altered  consciousness  or  personality,
seizures, or focal neurological signs; iii) pres-
ence of anti-dengue Immunoglobulin M anti-
bodies  or  dengue  genomic  material  in  the
serum  and/or  cerebrospinal  fluid  (which  of
these should be assayed for should be deter-
mined according to time from onset of infec-
tion);  iv)  exclusion  of  other  causes  of  viral
encephalitis and encephalopathy.
The  main  symptoms  are  seizures,  altered
consciousness, and headaches. Unexpectedly,
the  typical  symptoms  of  dengue  infection
(myalgias, diarrhea, joint or abdominal pain,
rash, and bleedings) are reported in only 50%
of  encephalitis  cases.29,30 Therefore,  dengue
virus would not ordinarily be suspected to be
the cause of the neurological disease.31
The computed tomography (CT) and mag-
netic resonance imaging (MRI) findings are
diverse.  Normal  parameters  are  not  uncom-
mon but hemorrhages, diffuse cerebral edema,
and focal abnormalities involving the globus
pallidus, the hippocampus, the thalamus, and
the internal capsule can also be found. These
lesions  are  hyper-intense  as  visualized  by
MRI.24 Analysis  of  CSF  can  demonstrate
inflammatory  reaction,  with  lymphomononu-
clear  pleocytosis  and  normal  glucose  levels.
However,  normal  CSF  cellularity  has  been
shown  in  more  than  half  of  patients  with
dengue encephalitis.10 The absence of pleocy-
tosis in CSF has been described in 5% of viral
encephalitis  cases;  we  speculate  that  this
number  is  underestimated  with  regard  to
dengue infection.32 Therefore, the diagnosis of
encephalitis should not be discarded because
of normal CSF cellularity.10
The incidence of meningitis among serolog-
ically  confirmed  dengue  cases  ranges  from
24.4% to 30% in children.28 Dengue meningitis
rarely manifests in adults.22 Clinical signs are
similar to other viral meningitis. 
Acute disseminated
encephalomyelitis 
Acute  disseminated  encephalomyelitis
(ADEM) is rarely described in association with
dengue  infection.25,33-36 One  of  the  reported
cases was neuromyelitis optica, an exceptional
form of ADEM.25 The diagnosis of ADEM was
based on the onset of neurological symptoms
following the hyperpyrexic phase of dengue. As
with other viruses, the pathogenetic mecha-
nisms  underlying  ADEM  suggest  that  the
symptoms  result  from  an  immune  system-
mediated process. White matter lesions occur
in several areas of the brain, such as the cen-
trum semiovale, the corona radiata, the callos-
al-septal interface, and the thalamus. Thoracic
spinal  cord  can  also  be  involved,  showing
demyelinating lesions.34
An autopsy was described in only one case
in  the  literature.  Histopathology  from  the
lesions  showed  perivenous  demyelination,
macrophages  and  hemorrhages.  As  this
patient  had  dengue  hemorrhagic  fever,  the
focal hemorrhages seen in the lesions were
probably  related  to  the  patient’s  thrombocy-
topenia.36
Encephalomyelitis  secondary  to  dengue
infection  usually  has  a  favorable  outcome,
although  some  patients  exhibit  persistent
neurological  symptoms.  Glucocorticoid  is
effective in treating encephalomyelitis, which
is why an early diagnosis is critical for a good
prognosis.34-36
Myelitis
Myelitis  due  to  dengue  infection  is  an
uncommon neurological manifestation. Its fre-
quency ranges from 9.5% to 15%.8,27 Dengue
myelitis appears between seven and 30 days
following  the  onset  of  dengue  infection.27
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Table 1. Neurological complications according to pathogenesis.
Metabolic disturbance Viral invasion Autoimmune reaction
Encephalopathy Encephalitis Acute disseminated encephalomyelitis
Meningitis Neuromyelitis optica
Myositis Optic neuritis
Myelitis Myelitis
Post-infectious encephalopathy
Guillain Barré syndrome
Non-commercial use onlyNeurological symptoms may persist and may
include paraparesis and sphincter dysfunction.
MRI usually demonstrates lesions at the tho-
racic  spinal  level  where  there  is  a  hyper-
intense signal (Figure 1).24 A unique case in
which a gray matter abnormality was observed
using MRI in a region corresponding to the
anterior horn from the cervical to thoracic cord
has been reported.37 Analysis of CSF reveals an
increase in the albumin quotient (Alb Q) indi-
cating a dysfunction of the blood-CSF barrier
and the intrathecal synthesis of Immunoglob-
ulin G (IgG) dengue antibodies.9Based on spe-
cific  antibody  index,  Puccioni-Sohler  et  al.
found intrathecal synthesis of dengue IgG anti-
bodies only in patients with myelitis despite
also  examining  cases  of  encephalitis  and
GBS.9,38,39
Guillain Barré syndrome and
mononeuropathies
In  isolated  reports,  dengue  virus  was
described as a causative agent of GBS. In a pre-
vious  study,  Soares  et  al  reported  that  GBS
accounted for 30% of the neurological manifes-
tations of dengue infection.27 However, dengue
infection may have been underestimated as a
causative agent of GBS.40 The authors reported
seven cases (46.6% of all included GBS cases),
presenting with dengue positive IgM in serum
but with little to no clinical symptoms of the
previous infection. The neurological picture of
GBS cases induced by dengue infection is sim-
ilar to that described in the literature concern-
ing GBS caused by other infections in which
ascending paraparesis is the principal manifes-
tation.41-45 Treatment is usually effective and
the prognosis is good. A single case of Miller
Fisher  that  had  dengue  infection  was  also
reported to have recovered spontaneously.46
Evidence suggests that the clinical manifes-
tations of GBS are the result of cell-mediated
immunological  reactions.  Activated  T  cells
could cross the vascular endothelium (blood-
brain barrier) and recognize an antigen in the
endoneural  compartment.  T  cells  produce
cytokines  and  chemokines  which  open  the
blood-brain  barrier  allowing  antibodies  to
enter and Schwann cells to attack.47 Dengue
virus would initiate this immunological event,
leading to the disease. Myelin or axons could
be the target of this immune response.15
In  conclusion,  oligosymptomatic  dengue
underestimates the number of cases of GBS
associated with dengue infection. This situa-
tion is complicated by the long period of time
between  onset  of  infection  and  neurological
symptoms. In endemic areas, dengue infection
should be tested as a possible etiological agent
in cases of GBS. Finally, rare cases of long tho-
racic  neuropathy,  oculomotor  palsy,  and
phrenic  neuropathy  have  been  related  to
dengue infection.48-50
Myositis
Several viruses have been associated with
inducing benign acute myositis. In a study in
India, 50% of benign acute childhood myositis
cases  were  attributed  to  dengue  infection.23
Myositis has a wide clinical spectrum, ranging
from mild proximal asymmetrical weakness of
the lower limbs to severe, rapidly progressing,
Review
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Figure 1. A and B Magnetic resonance image of dorsal spinal cord showing an enhanced
signal in a patient presenting acute myelitis. Sagittal plane, T2 sequence.
Figure  2.  Two  percent  agarose  gel  elec-
trophoresis demonstrating the sized ampli-
cons for  dengue Multiplex RT-PCR. Lane
1: molecular size standard (100 bp), Lane
2: Dengue 3 in plasma (290 bp), Lanes 3-
4: negative samples, Lanes 5-6: Dengue 2
(119 bp) in both samples, Lane 7: negative
sample,  Lane  8:  Dengue  2  control  (119
bp),  Lane 9: Dengue 3 control (290 bp),
Lane 10: negative control. 
Non-commercial use onlylimb, trunk, and respiratory muscle weakness.
Usually, myositis is considered a benign illness
in  which  severe  fulminant  cases  are  rare.
Serum  creatine  phosphokinase  levels  are
always  elevated,  and  a  possible  correlation
between these values and the severity of the
weakness has been proposed.51 Muscle biop-
sies have revealed histopathological changes,
including perivascular mononuclear infiltrate,
lipid accumulation, foci of myonecrosis, and an
increase in the number of mitochondria.52
The  pathogenesis  of  myositis  is  not  clear.
Direct  viral  invasion  and  immune-mediated
damage of muscle fibers have been suggested to
be  possible  mechanisms.  Immune-mediated
damage of muscle fibers has also been implicat-
ed in rhabdomyolysis. In addition, biochemical
and hematologic abnormalities, such as throm-
bocytopenia, leukopenia, and hypokalemia, are
potential factors that influence the severity and
prognosis of dengue myositis.53,54
Laboratory studies
The diagnosis of acute dengue infection is
based  on  the  detection  of  viral  antigens  or
antibodies in blood.55-57 Viral antigens may be
detected in blood or CSF during the first week
after the onset of symptoms by such technique
as  cell  culture  or  tissue  fixation,  enzyme-
linked immunosorbent assay (ELISA), or poly-
merase chain reaction (reverse-transcriptase
PCR or real-time PCR) (Figure 2).11,16,31,58 The
detection of dengue IgM antibodies in serum
or the increase of dengue IgG antibody titer in
paired samples can be used to confirm serolog-
ical  diagnosis  of  a  recent  infection.55,59,60
Specific serum reactivity for IgM may be found
five days after the onset of symptoms and may
persist for 30-60 days. Meanwhile, an increase
in  dengue  IgG  antibodies  occurs  during  the
first or second day in cases of secondary infec-
tion.  Specific  IgG  antibody  levels  return  to
baseline levels after 30-40 days.55 The detec-
tion of specific antibodies is usually accom-
plished by ELISA but may also be detected by a
complement fixation technique, a neutraliza-
tion test, a hemagglutination inhibition assay,
or  an  immunochromatographic  rapid  test.55
Serum cross-reactivity is common in the sero-
logical tests with other flaviviruses, such as St.
Louis  encephalitis,  Japanese  encephalitis,
West Nile fever, and yellow fever.60
Analysis of CSF contributes to the neurolog-
ical diagnosis associated with dengue by the
demonstration of: i) inflammatory reaction in
the  CNS  (pleocytosis,  hyperproteinorhachia,
blood-CSF barrier dysfunction, and intrathecal
synthesis of total IgG) in cases of encephalitis,
myelitis, and meningitis; ii) protein-cytologi-
cal  dissociation  in  Guillain  Barré  syndrome;
iii)  hemorrhagic  CSF  in  cases  of  cerebro-
meningeal hemorrhage; iv) exclusion of other
infectious diseases; and v) detection of specif-
ic antibodies and viral antigens.9,11,31 However,
normal CSF does not exclude the possibility of
neurological  complications  associated  with
dengue.  Complications  may  occur,  especially
in cases of encephalitis.10 Specific IgM and IgG
antibodies have been found in CSF in the early
stages of dengue CNS infection up until 5-7
days after the onset of neurological symptoms.
The  dengue  IgM  immune  response  in  CSF
detected by ELISA shows a high specificity (97-
100%)  the  neurological  diagnosis  associated
with dengue to be confirmed.
The  sensitivity  of  IgM  detection  in  CSF
ranges between 0% and 73%, depending on the
method  used.  The  absence  of  specific  IgM
detection in CSF does not exclude dengue as
the  causative  agent.7,11,17,27,61 On  the  other
hand, specific IgG in CSF is not useful as a
diagnostic tool, as these antibodies may result
from  a  prior  infection,  and  they  cross  the
blood-CSF barrier. The presence of intrathecal
synthesized specific antibodies is a potential
marker of myelitis associated with dengue and
seems  to  be  related  with  the  neuroinvasive
properties of the virus.9 Non-structural 1 anti-
gen (NS1 Ag) was found in the CSF of dengue
patients by ELISA as detected by an assay that
exhibited a sensitivity of 50% and specificity of
100%.11 The combined use of NS1 Ag and spe-
cific IgM antibodies increased the sensitivity
of dengue analysis in CSF to 92%.11 The fre-
quency of detection of dengue viral RNA, using
PCR  techniques  (RT-PCR  or  real-time  PCR)
has  had  variable  success  in  CSF  (0-
83%).7,8,16,31 It depends on the neurovirulent
and  neuroinvasive  phenotype  of  studied
dengue  virus,  the  stage  of  the  disease,  and
which method is employed. In fact, not all neu-
rological  complications  associated  with
dengue are caused by the direct virus neuroin-
vasion. 
Diagnosis
A diagnosis of neurological disease associat-
ed with dengue is made by detecting the pres-
ence of positive dengue IgM or viral antigens in
patients  with  acute  neurological  symptoms.6
Diagnosis may be difficult because of the pos-
sible  development  of  neurological  complica-
tions in oligosymptomatic dengue cases, and
the routine test of CSF is not specific. Blood
tests, CSF analysis and MRI images contribute
to the differential diagnoses, as do a number of
other  inflammatory,  neoplastic,  and  vascular
diseases.  Routine  hematologic,  biochemical,
and liver function tests for rheumatic diseases,
B/C  hepatitis,  and  human  immunodeficiency
virus-1  (HIV-1)  should  be  carried  out  in  all
patients. Routine CSF analyses include a cell
count,  a  determination  of  protein  and
glucose/lactate concentration, a smear and cul-
ture for bacteria and fungi, an assessment of
blood-CSF barrier function by albumin quotient
(CSF/serum), a detection of intrathecal synthe-
sis of total IgG, and a measurement of specific
antibodies  against  syphilis,  cytomegalovirus,
Epstein-Barr, and herpes simplex viruses.
Treatment and prognosis 
There  is  no  licensed  vaccine  or  specific
treatment to prevent dengue or the neurologi-
cal diseases associated with it.62 The only pre-
ventative  measure  is  to  avoid  catastrophic
dengue  epidemics  through  the  control  of
dengue vectors.2 Neurological diseases associ-
ated with dengue may be treated according to
diagnosis.  The  majority  of  patients  have  a
benign evolution with spontaneous recovery,
especially  those  who  have  encephalitis  or
Guillain-Barrè syndrome.27 The prognosis and
the characteristics of Guillain-Barrè syndrome
seem to be similar to those reported for other
infectious  diseases.  Neurological  sequelae
occur in 20-30% of reported cases;8,27,38 these
include spastic paraparesis and urinary reten-
tion associated with cases of myelitis. Mental
confusion  and  personality  alterations  have
remained  in  some  patients  with  dengue
encephalitis. Mortality from dengue infection
is 3-5%.6 The mortality rate of patients who
develop  neurological  complication  associated
with dengue depends on the clinical picture of
the  disease  and  ranges  between  5%  and
30%.7,24,27,28,38 In general, this mortality results
from cases of DHF or dengue shock syndrome.
Conclusions
Diagnosis of neurological dengue needs to be
reevaluated,  especially  for  clinicians  who  are
unfamiliar with its wide array of clinical presen-
tations.  Diagnosis  is  currently  based  on  the
detection of specific IgM antibodies or antigens
in the blood. In addition, analysis of CSF (for the
detection of specific antibodies and viral anti-
gens)  has  demonstrated  great  potential  as  a
diagnostic tool for neurological dengue as well
as for providing a better understanding of the
dengue neuropathogenesis. In endemic areas
or in cases of recent travel to endemic regions,
dengue infection should be considered in the
differential diagnosis of encephalitis, myelitis,
Guillain-Barrè syndrome, and meningitis, even
in the absence of a previous history of dengue
fever. The neurological complications associat-
ed with dengue may be underestimated, espe-
cially  in  cases  in  whom  there  was  a  prior
oligosymptomatic/asymptomatic  dengue  infec-
Review
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Non-commercial use onlytion.  Improving  the  accuracy  of  diagnosis  is
important for the early treatment of the neuro-
logical complications, thereby avoiding unnec-
essary therapy and longer hospitalization, while
searching for the presence of other diseases.
More than ever, the development of a dengue
vaccine needs to be the focus of research efforts
seeking to control the disease.
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